www.nature.com/nrneurol NEWS & VIEWS associated with GRN mutations. Conversely, in the UK study, a brain autopsy on one patient with a C9orf72 mutation revealed FTLD-tau with corticobasal degeneration (CBD), 4 representing the only report of a diagnosis other than FTLD-TDP or ALS with this mutation. This finding, if correct, calls into question the specificity of the C9orf72 mutation for FTLD-TDP. Chromosome 9p linkage and a subsequent finding of C9orf72 hexa nucleotide repeat expansion has previously only been reported in cases of ALS, with or without dementia. However, exclusion of patients with MAPT and GRN mutations or FTLD-tau pathology, as in the Netherlands study, 3 might cause 'outliers' as seen in the UK study to be missed.
Both studies report the results of immunostaining using an antibody to the C9orf72 protein. The two groups found dif fuse and granular cytoplasmic labelling of neurons in areas affected by pathology in FTLD-TDP and ALS, but this feature was present in all cases, including controls, and was considered to be physio logical.
3,4 C9orf72-positive hippocampal CA4 synaptic arbori zations extending into areas CA2-3 were also observed. The Netherlands group found this labelling in cases of FTD with and without the repeat expansion.
3 By contrast, the UK group found this labelling to be strong in healthy controls, variably pre served in cases of MND, but decreased or absent in some patients with FTLD and not markedly di fferent in those with C9orf72 mutations.
4
Both groups found p62-positive TDP-43-negative inclusions in cere bellar granular neurons, 3,4 as has previously been reported.
8,9
These inclusions were not labelled with the C9orf72-specific antibody; the identity and significance of the inclusion protein, therefore, remain unknown. Although previously thought to be specific for C9orf72 cases, these inclusions were not found by Snowden et al. in the C9orf72 mutation carrier with FTLDtau (CBD) pathology, and were detected in three cases of FTLD-TDP seemingly without a C9orf72 mutation. 4 If the absence of a repeat expansion in these three cases proves to be true, the inclusions may not be specific to cases with C9orf72 repeat expansion, as has been previously reported. 8, 9 RNA misprocessing might be the pathophysiological link between C9orf72 mutation and FTD-ALS, as intranuclear RNA foci have been observed in cases with C9orf72 repeat expansion.
1 Simon-Sanchez et al. were unable to confirm this finding, 3 possibly owing to use of a different RNA probe from that employed in previous studies. Other dis orders with repeat expansion are associated with RNA misprocessing, which has provided researchers with testable potential therapeutic targets.
These two new reports confirm that C9orf72 repeat expansion is common in famil ial cases of FTD-ALS.
3,4 Unique findings from the UK study, such as the association of the mutation with psychosis, remain to be confirmed by others. 4 As more is learned about the clinical and patho logical characteristics of this genetic FTLD subtype, it is hoped that the threads linking ALS and FTD will be better understood, ultimately enabling the design of a targeted therapy for these disorders. 
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NEURODEGENERATIVE DISEASE
Establishing a clinical trial battery for Huntington disease
Jane S. Paulsen and Jeffrey D. Long
The success of clinical trials in Huntington disease (HD) will depend to a large degree on the quality of the outcome measures. Using data from the TRACK-HD study, a recent publication proposes a battery of assessments that could be used as outcomes in future clinical trials in patients with early HD. participants were classified at baseline into two groups, preHD-A and preHD-B, on the basis of predicted proximity to HD diagnosis, with the latter group being closest to diagnosis. Participants with an HD diagnosis were also classified into two groups (HD1 and HD2) according to their level of functioning (HD1>HD2). An additional two groups, progressors and non-progressors, were later formed from the pre manifest participants on the basis of presence or absence, respectively, of appreciable progression over time.
With the 91% of participants who were retained from baseline assessments, a range of variables was monitored over the 24-month period. These variables included clinical ratings of motor abnormality, functional capacity and psychiatric symptoms; objective standardized assessments of cognition and quantitative motor measures; and neuroimaging measures derived from 3T MRI brain scans. Of 21 outcome measures reported (using P <0.01 for multiple comparisons), 17 showed significant differences for participants with HD (HD1 plus HD2) when compared with changes in normal controls. For the premanifest gene carrier groups, only three measures -putamen volumes, caudate volumes, and total motor score-showed significant changes when compared with normal controls. Three additional MRI measures showed significant brain volume changes in progressors relative to non-progressors.
Among the six imaging measures that were considered, change rates for putamen and caudate volumes were significantly greater in all HD groups than in healthy controls. Three measures-whole-brain volume, ventricular volume, and white matter volume-were significantly different from control values in both the diagnosed HD and preHD-B groups, whereas changes in grey matter only diverged from control values in the diagnosed HD groups. The diagnosed groups differed significantly from the controls on four of five cognitive outcome scores (symbol digit modality test, Stroop word reading, circle tracing-direct, and circle tracing-indirect). None of the 24-month change scores for the cognitive outcomes showed significant variations between the premanifest gene carrier group and the controls. Of five quantitative motor scores that were compared across groups, chorea position, grip force variability and tapping speed measures all differed markedly between the control and diagnosed HD groups. Clinical motor rating scale scores were significantly different for all HD groups when compared with normal control changes, whereas changes on functional capacity and apathy were only significantly different for the diagnosed groups.
The results of the Tabrizi et al. study culminate in a table of TRACK-HD assessments that are proposed to be used as outcome measures for future clinical trials in early HD. The authors also provide sample size and statistical power calculations for different effect sizes in the recommended battery of measures.
TRACK-HD has met the stated goals, and has provided excellent multisite, prospective, longitudinal data for 24-month followup of a cohort of early-stage and premanifest individuals with HD. The four sites and the CHDI leadership should be lauded for this efficient study, and other disease special ties and academic groups could benefit from adopting this type of paradigm. How ever, the integration of the Tabrizi et al. data into the extant literature and its utility for perpetual research endeavours require careful consideration. The analysis focused on statistical effect size, but each candidate measure within a clinical battery should also be evaluated in terms of feasibility (for example, cost), psycho metric rigour (for exam ple, reli ability across sites), normative stan dards (stage of disease as well as normal control variation), and participant burden (for example, frustration level).
The Tabrizi et al. analysis considered each variable in isolation, so the issue of unique contribution of individual measures was not addressed. A multivariate approach -though not easy to perform-would provide information about the specific utility and power of individual measures above and beyond the numerous measures already available. The proposed battery might then be reduced even further by eliminating redundancy without sacrificing efficiency. For example, motor impairment might validly be indexed by a subset of the six measures considered in the analysis.
A challenge in any study of HD is the classification of disease progression at the start of the study. Accurate classification is essential to identifying which tools are appro priate markers for particular indivi duals. Tabrizi et al. go a long way in this regard by using the thoughtful classification strategy previously mentioned. As with all ordered categories of progression based on multiple criteria, it is unclear what portions of the disease progression spectrum are represented by the groups. For example, the traditional definition of motor diagnosis might be too cautious. In addition, a gap, representing an intermediate status, might exist between the premanifest and manifest groups. This scenario is depicted in Figure 1 , which shows the four initial Tabrizi et al. groups depicted by solid boxes, and the potentially omitted group represent ed by the dashed box.
The results of the study showed an appreciable increase in effect size when stepping up from preHD-B to HD1. Inclusion of intermediate groups might be helpful in determining whether effect-size change is gradual or sudden. The potential benefit of such an approach is the identification of critical points along the disease progression at which particular tools gain or lose sensitivity. Such information is important to maximize resources for future clinical trials.
